European Union: High Court Grants Declaratory Relief In Pharmaceutical Regulatory Dispute

Last Updated: 17 June 2016
Article by Andrew Payne

In the recent case of Accord Healthcare Ltd and another v Astellas Pharma GmbH and another [2015] EWHC 3676 (Ch), the High Court has declared that a marketing authorisation, granted in 2005 under transitional provisions applicable following German reunification, was fully compliant with European law and the drug could therefore be relied upon as a "reference medicinal product" in accordance with Directive 2001/83/EC.


Directive 2001/83/EC (the "Directive") sets out detailed requirements that must be met by an applicant seeking marketing authorisation for a medicinal product. By way of derogation from these requirements, Article 10(1) provides that following expiry of a certain period of time (the "exclusivity period"), a generic manufacturer is entitled to obtain its own marketing authorisation without providing the results of pre-clinical tests and clinical trials if its application is for a generic of a medicinal product which has been authorised by a Member State in accordance with the Directive (a "reference medicinal product").

In July 2005, Astellas obtained marketing authorisation from the German regulatory authority ("BfArM") for its bendamustine anti-cancer product Ribomustin®. In 2013 and following expiry of the exclusivity periods in the 6-year countries, Accord applied for, and was granted, marketing authorisations in a number of European countries for its generic bendamustine product. Accord cited Ribomustin® as the reference medicinal product. However, Astellas repeatedly challenged these marketing authorisations, alleging that the approval of Ribomustin® in 2005 did not constitute a marketing authorisation within the meaning of the Directive, and therefore could not be relied upon by Accord (or any other generic manufacturer) as a reference medicinal product. In particular, Astellas argued that the 2005 marketing authorisation granted by BfArM had not been properly reviewed and/or had otherwise been revoked retrospectively. Astellas had obtained a later marketing authorisation in 2010 for its bendamustine product Levact and claimed that this was the proper reference medicinal product for the purpose of calculating the start of the exclusivity period.

Astellas's numerous challenges in the 6-year countries disrupted the launch of generic bendamustine and in some cases resulted in the automatic suspension of the marketing authorisation.

Faced with uncertainty in the 10-year countries, Accord took the unusual and proactive step of seeking a positive declaration from the High Court that Ribomustin® was the correct reference medicinal product within the meaning of the Directive, in order to clear the way for the launch of its bendamustine product in the UK. The declaration was sought before expiry of the exclusivity period.

The key issues considered by the Court

Was the 2005 BfArM authorisation a marketing authorisation in accordance with the Directive?

The 2005 marketing authorisation granted by BfArM for Ribomustin® was an extension of a deemed authorisation that took effect by operation of law for medicinal products already in clinical use at the time of German reunification. Following submission of the required dossier, the extension was granted under s.105 of the German Medicinal Products Act ("AMG") in respect of two of the three indications sought by Astellas, but was subject to a number of conditions relating to the pharmaceutical quality of the product. In the current case, Astellas submitted that BfArM were not permitted to issue a conditional authorisation pursuant to s.105 AMG and that the marketing authorisation granted by BfArM in 2005, Astellas alleged, was therefore not compliant with the Directive. As a consequence Ribomustin® could not constitute a reference medicinal product triggering the start of the exclusivity period.

Even if the court were to consider that marketing authorisations with conditions were generally permitted under the Directive, Astellas submitted that since the conditions imposed in this particular case related to allegedly "serious deficiencies" in the dossier submitted, the 2005 authorisation was not in substance a Directive-compliant authorisation. As a consequence, Astellas argued that Ribomustin® could not be relied upon as a reference medicinal product under Article 10(1) of the Directive.

Did a settlement agreement concluded between Astellas and BfArM in 2011 render the 2005 decision void ab initio?

Following BfArM's decision in 2005, Astellas launched an appeal against BfArM's refusal to grant marketing authorisation for one of the indications sought for Ribomustin®. This appeal was eventually settled in 2011.

Astellas argued that the settlement agreement between BfArM and Astellas had retrospective effect, thereby rendering the 2005 marketing authorisation decision void ab initio for all three indications. As a consequence, the 2005 marketing authorisation for Ribomustin® did not trigger the start of the 10-year data exclusivity period provided for under the Directive and could not be relied upon by Accord (or any other generic manufacturer) for the purpose of launching a generic bendamustine product.


The Court dismissed Astellas's arguments and found in favour of Accord in all respects, granting the positive declaration sought by Accord that Ribomustin® is a reference medicinal product within the meaning of the Directive.

Morgan J. held that there were repeated references in the Directive suggesting that the competent authority, when granting a marketing authorisation, could impose conditions or post-authorisation controls. The marketing authorisation granted by BfArM in 2005 was consistent with this and the wording of the authorisation quite clearly stated that it could be suspended or revoked if the conditions imposed were not fulfilled within the required timeframe. Morgan J. also held that the conditions did not indicate there were any "serious deficiencies" or that BfArM went beyond the powers of a competent authority under the Directive in imposing them.

In relation to the settlement agreement, Morgan J. held that even if Astellas had intended to void the 2005 marketing authorisation ab initio, the legal effect of the settlement was in fact to renounce the 2005 marketing authorisation from the date of the settlement agreement i.e. from the end of 2011. In pre-settlement correspondence BfArM had repeatedly refused to annul the decision in the retrospective manner suggested by Astellas. Furthermore, under German administrative law, a lawful administrative act such as this could only be revoked prospectively, not retrospectively.


In the judgment, Morgan J. stated that the usual method for challenging a marketing authorisation was by judicial review. However, taking into account Astellas's previous pattern of challenging Accord's marketing authorisations in other countries, frequently leading to their automatic suspension, Accord sought a positive declaration from the UK Courts to obtain clarity ahead of the expected UK marketing authorisation in November 2015. Furthermore, both parties were in agreement that the declaratory proceedings would serve a useful purpose in resolving the key issues in dispute.

This case is an example of the UK Courts acting in an innovative way to resolve a large-scale commercial dispute very quickly. The trial was heard on an expedited basis, with the time from starting the action to judgment being just over four months. The case involved the consideration of complex issues of European pharmaceutical regulatory law and German administrative law and also triggered three unsuccessful interim relief applications and judicial reviews being sought against the MHRA and at least six other parties. The cases continue in various countries around Europe.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.